UK: Myricx Bio raises £90m series A financing to advance its NMTi-ADC therapeutics into clinical development

Myricx Bio, a UK biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), has closed a £90m (US$114m) series A financing, […]